The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis

被引：0
|
作者：
Lihu Gu
Parikshit Asutosh Khadaroo
Hui Su
Liya Kong
Liangliang Chen
Xianfa Wang
Xinlong Li
Hepan Zhu
Xin Zhong
Junhai Pan
Manman Chen
机构：
[1] University of Chinese Academy of Sciences,Department of General Surgery, HwaMei Hospital
[2] Monash University School of Public Health and Preventive Medicine,Department of Surgical Oncology, HwaMei Hospital
[3] Zhejiang Chinese Medical University,Department of General Surgery
[4] University of Chinese Academy of Sciences,undefined
[5] Zhejiang University School of Medicine Sir Run Run Shaw Hospital,undefined
[6] Affiliated Hospital of Medical School Ningbo University and Ningbo City Third Hospital,undefined
来源：
BMC Cancer | / 19卷
关键词：
PD-1; PD-L1; CTLA-4; Adverse events; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Distinct cellular mechanisms mediate anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Wei, Spencer C.
    Levine, Jacob H.
    Pe'er, Dana
    Allison, James P.
    [J]. CANCER RESEARCH, 2017, 77
  • [32] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Celine Boutros
    Ahmad Tarhini
    Emilie Routier
    Olivier Lambotte
    Francois Leroy Ladurie
    Franck Carbonnel
    Hassane Izzeddine
    Aurelien Marabelle
    Stephane Champiat
    Armandine Berdelou
    Emilie Lanoy
    Matthieu Texier
    Cristina Libenciuc
    Alexander M. M. Eggermont
    Jean-Charles Soria
    Christine Mateus
    Caroline Robert
    [J]. Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
  • [33] Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
    Wei, Spencer C.
    Levine, Jacob H.
    Cogdill, Alexandria P.
    Zhao, Yang
    Anang, Nana-Ama A. S.
    Andrews, Miles C.
    Sharma, Padmanee
    Wang, Jing
    Wargo, Jennifer A.
    Pe'er, Dana
    Allison, James P.
    [J]. CELL, 2017, 170 (06) : 1120 - 1133
  • [34] Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Wei, Spencer
    Levine, Jacob
    Cogdill, Alexandria
    Zhao, Yang
    Anang, Nana-Ama
    Andrews, Miles
    Sharma, Padmanee
    Wang, Jing
    Wargo, Jennifer
    Pe'er, Dana
    Allison, James
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [35] Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis
    Habibi, Mohammad Amin
    Mirjani, Mohammad Sina
    Ahmadvand, Muhammad Hussain
    Delbari, Pouria
    Eftekhar, Mohammad Shahir
    Ghazizadeh, Yalda
    Ghezel, Mohammad Amin
    Rad, Romina Hamidi
    Vakili, Kimia Ghazi
    Lotfi, Sohrab
    Minaee, Poriya
    Eazi, Seyedmohammad
    Mehrizi, Mohammad Ali Abouei
    Ahmadpour, Sajjad
    [J]. NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [36] Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
    Huang, Shuang
    Zheng, Gang
    Yang, Kai
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [37] Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
    Shuang Huang
    Gang Zheng
    Kai Yang
    [J]. World Journal of Surgical Oncology, 21
  • [38] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
    Chen, Ke
    Wang, Xiao
    Yang, Liu
    Chen, Zheling
    [J]. CANCER CONTROL, 2021, 28
  • [39] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    [J]. Drug Safety, 2019, 42 : 281 - 294
  • [40] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    [J]. DRUG SAFETY, 2019, 42 (02) : 281 - 294
12345